Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01264783 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of RNS60 Given by IV to Healthy Subjects
A Phase 1 study of Myocardial Infarct, sponsored by Revalesio Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01264783 is a Phase 1 study of Myocardial Infarct that has completed, run by Revalesio Corporation. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01264783, a Phase 1 study of Myocardial Infarct, has completed, sponsored by Revalesio Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the safety and tolerability of RNS60 administered intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three escalating rates for 48 hours for each rate.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RNS60
Study Locations (1)
Kansas
- Quintiles, Inc. - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01264783
The ClinicalTrials.gov registry entry for NCT01264783 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revalesio Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myocardial Infarct appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01264783 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT01264783 about?
NCT01264783 is a clinical study titled "Safety and Tolerability of RNS60 Given by IV to Healthy Subjects". The objective of this study is to evaluate the safety and tolerability of RNS60 administered intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three escalating rates for 48 hours for each rate.
What is the current status of trial NCT01264783?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-07. Estimated completion is 2011-09.
What conditions does trial NCT01264783 study?
This clinical trial studies the following conditions: Myocardial Infarct.
What interventions are being tested in trial NCT01264783?
The interventions under investigation include: Placebo (DRUG), RNS60 (DRUG).
Who is sponsoring clinical trial NCT01264783?
This trial is sponsored by Revalesio Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01264783 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarct
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.